Business context and reporting period
Entity discrepancy: The supplied filing is Miragen Therapeutics, Inc.’s Form 10-Q for the quarter ended March 31, 2018, not a filing for Viridian Therapeutics, Inc. The summary below reflects the filing text provided.
Miragen was a clinical-stage biopharmaceutical company developing RNA-targeted microRNA therapies. Its clinical-stage candidates were cobomarsen, MRG-201 and MRG-110. It had no approved products and had generated no product-sales revenue.
Key financial metrics
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Revenue | $4.784 million | $0.462 million |
| Research and development expense | $6.413 million | $4.120 million |
| General and administrative expense | $2.990 million | $3.281 million |
| Operating loss | $4.619 million | $6.939 million |
| Net loss | $4.661 million; $0.18 per share | $6.980 million; $0.60 per share |
| Cash used in operating activities | $7.361 million | $8.183 million |
Revenue included a $3.7 million development milestone earned under the Servier collaboration and $1.1 million of reimbursable research and development and intellectual-property activities. Grant revenue fell by approximately $0.4 million year over year. No gross margin is presented; revenue was primarily collaboration and grant revenue, not product sales.
At March 31, 2018, cash and cash equivalents were $78.099 million, total current assets $86.353 million, and current liabilities $4.137 million. Notes payable had a carrying value of $10.018 million ($10.0 million principal); total liabilities were $14.286 million. Accumulated deficit was $98.254 million. The company reported a $37.9 million net public-offering raise in February, issuing 7,414,996 shares at $5.50 per share; period-end common shares outstanding were 30,186,540, up from 22,568,006 at year-end 2017.
Financing cash flow was $38.114 million, while investing cash flow used $0.095 million. Management estimated the existing cash balance would fund operations into early 2020. The filing also states that cash needs could be greater than anticipated and that additional capital will be required to continue development.
Material changes and developments
- Revenue rose mainly because Miragen earned its first Servier development milestone after initiation of the MRG-110 Phase 1 trial in March 2018.
- R&D expense increased $2.3 million, primarily from personnel costs, technology license fees and clinical development. G&A expense decreased $0.3 million, largely because the prior-year quarter included merger-related legal and professional costs.
- Net loss narrowed by $2.3 million year over year, while operating cash use fell by $0.8 million. The cash-flow improvement was partly offset by higher receivables related to the Servier milestone.
- The February public offering materially increased cash and share count. The company also had an at-the-market facility of up to $50 million; it reported no ATM sales during Q1 2018.
- After quarter-end, Miragen and Servier amended their agreement to update MRG-110 development and cost-sharing provisions. In April, Miragen filed an IND for MRG-201 and planned a Phase 2 trial in keloid-prone subjects for Q2 2018. In May, it reported closing enrollment in the cobomarsen Phase 1 CTCL trial and starting a second MRG-110 Phase 1 trial.
Outlook, risks and unusual items
Management expected R&D expense and operating losses to increase as clinical trials and preclinical programs advance, and warned that losses may fluctuate significantly. The company’s estimates placed its cash runway into early 2020, but that outlook depended on assumptions about development pace, collaboration funding and cash consumption.
- Key risks include early-stage clinical uncertainty, the unproven microRNA approach, safety and delivery challenges, regulatory approval risk, dependence on third-party manufacturers and trial operators, and reliance on collaborations and intellectual-property licenses.
- Miragen had a $10 million variable-rate Silicon Valley Bank loan bearing interest at prime (4.75% at March 31, 2018), with a $0.9 million final payment fee due at maturity. The loan is secured by business assets other than intellectual property and contains restrictive covenants and default provisions.
- The Servier milestone and receivable were significant to quarterly revenue and working capital. Further milestone, royalty and reimbursement revenue depends on development progress and agreement terms.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls at quarter-end. Clinical-trial accruals and collaboration revenue timing rely on estimates.
Most important facts for investors to verify
- Confirm the issuer: this source is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Verify the $3.7 million Servier milestone’s conditions, collectability and payment timing, along with ongoing reimbursement under the amended collaboration.
- Assess whether the stated cash runway into early 2020 remains credible against quarterly operating cash use, planned trial spending and the need for additional capital.
- Track clinical progress and safety data for cobomarsen, MRG-201 and MRG-110, including whether stated trial plans were initiated and met their endpoints.
- Review dilution from the public offering, potential future ATM sales, equity compensation and outstanding options.
- Monitor SVB loan covenants, variable-rate exposure, maturity payments and the consequences of any default.